Since a subpopulation of the C-terminal MET-positive patients show no immunoreactivity for the N-terminus, and therefore are presumed to show a suboptimal response to MET moAbs, an association between the difference between C- and N-terminal MET (MET-EC-) and poor survival was also established [42,47], a result that is concurrent with the tumor-promoting potential of MET-EC- [45]. The gene discussed is MET; the disease is neoplasm.